Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafia Bhore

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Therapeutic Advances in Ophthalmology|August 21, 2025
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degenerationPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Therapeutic Advances in Ophthalmology|July 14, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDavid M Brown, David S Boyer, Diana V Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Open-label, Phase I Study of Nivolumab Combined with <i>nab</i>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic CancerZev A Wainberg, Howard S Hochster, Edward J Kim, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Therapeutic Advances in Ophthalmology|July 6, 2026
Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Ophthalmology|August 28, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR TrialJean-François Korobelnik, Paolo Lanzetta, Sergio Leal, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trialDavid M Brown, David S Boyer, Diana V Do, et al.
Neurobiology of Pain (Cambridge, Mass.)|December 15, 2023
Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis painSelin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, et al.
BMJ Open|October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 studyThomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Ophthalmology|November 12, 2025
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON TrialDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Therapeutic Advances in Ophthalmology|August 21, 2025
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degenerationPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Therapeutic Advances in Ophthalmology|July 14, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDavid M Brown, David S Boyer, Diana V Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Open-label, Phase I Study of Nivolumab Combined with <i>nab</i>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic CancerZev A Wainberg, Howard S Hochster, Edward J Kim, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Therapeutic Advances in Ophthalmology|July 6, 2026
Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Ophthalmology|August 28, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR TrialJean-François Korobelnik, Paolo Lanzetta, Sergio Leal, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trialDavid M Brown, David S Boyer, Diana V Do, et al.
Neurobiology of Pain (Cambridge, Mass.)|December 15, 2023
Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis painSelin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, et al.
BMJ Open|October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 studyThomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Ophthalmology|November 12, 2025
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON TrialDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Pageof 6